Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is desmoplastic small round cell tumor (dsrct)?
Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive soft-tissue sarcoma that occurs mostly in adolescents and young adults and affects males far more often than females. It belongs to the family of 'small round blue cell' tumors and is defined by a specific genetic change — a fusion of two genes called EWSR1 and WT1 — that can be confirmed on a biopsy and distinguishes it from other cancers it can resemble. DSRCT characteristically arises on the lining of the abdomen and pelvis (the peritoneum), where it tends to form not a single mass but many tumor nodules scattered across the abdominal surfaces, surrounded by dense scar-like tissue (the 'desmoplastic' part of its name). Because it grows in the spacious abdominal cavity, it often causes few symptoms until tumors are large or numerous, so many people have widespread disease in the abdomen, and sometimes spread to the liver, lungs, or lymph nodes, by the time it is found. Common symptoms include abdominal pain, swelling or a feeling of fullness, a palpable mass, and weight loss. DSRCT is a serious diagnosis, and no single treatment is enough on its own — it requires an intensive, coordinated combination of treatments. The standard approach uses aggressive chemotherapy to shrink the disease and treat tumor cells throughout the body, surgery to remove as much of the visible tumor as safely possible (often called aggressive cytoreduction or debulking), and radiation to the whole abdomen and pelvis to treat the microscopic disease that surgery cannot reach. Care at a center experienced with this rare cancer, ideally within a clinical trial, gives the best chance of the most effective combination.
The main types
Doctors group desmoplastic small round cell tumor (dsrct) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Abdominal/pelvic DSRCT (typical) | The usual presentation — many tumor nodules spread across the lining of the abdomen and pelvis; treated with the full combination of chemotherapy, surgery, and whole-abdominal radiation. |
| DSRCT with distant spread | Disease that has also reached the liver, lungs, or lymph nodes beyond the abdomen; treated with intensive systemic therapy, with surgery and radiation directed at the areas that can be controlled. |
| DSRCT outside the abdomen (rare) | Uncommonly, the tumor begins in another location such as the chest or a limb; the same gene fusion confirms the diagnosis, and treatment combines chemotherapy, surgery, and radiation as the situation allows. |
Staging, in plain terms
DSRCT is not staged with the usual TNM numbering. Because it so characteristically spreads across the lining of the abdomen as many nodules rather than forming one mass, doctors describe it instead by how widely it has involved the abdominal cavity, whether it has reached organs such as the liver or sites outside the abdomen such as the lungs or lymph nodes, and — crucially for planning treatment — how much of the visible tumor a surgeon will be able to remove. The amount of tumor that can be successfully removed (the completeness of surgical cytoreduction) is one of the most important factors in how the disease responds, because surgery, radiation, and chemotherapy work best together when the bulk of the cancer has been cleared. Imaging of the entire abdomen and pelvis, along with the chest, maps where the disease is, and a PET scan can help find all the sites. The practical questions that shape treatment are: how extensively is the abdomen involved, has the cancer spread beyond it, and how much of the tumor can be removed — all of which guide the intensity and sequencing of chemotherapy, surgery, and radiation.
| No standard TNM stage — DSRCT is described by how widespread the disease is within the abdomen, whether it has spread to the liver, lungs, or lymph nodes, and how much of it can be surgically removed | What it generally means |
|---|---|
| Abdominal disease, surgically removable bulk | Disease confined to the abdomen and pelvis where a surgeon can remove most of the visible tumor; treated with chemotherapy, aggressive surgery, and whole-abdominal radiation. |
| Extensive abdominal disease | Widespread tumor across the abdominal lining that limits how much can be removed; chemotherapy and radiation carry more of the load, with surgery removing what is feasible. |
| Disease spread beyond the abdomen | Tumor that has also reached the liver, lungs, or distant lymph nodes; treated with intensive systemic therapy, with local treatments aimed at controllable sites. |
The standard of care
Desmoplastic Small Round Cell Tumor (DSRCT) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Intensive chemotherapy
Multi-drug chemotherapy is the backbone of treatment, used first to shrink the widespread disease and treat tumor cells throughout the body before and after local treatments.
Aggressive surgical removal (cytoreduction)
Surgery to remove as much of the visible tumor as safely possible; the more completely the bulk of disease is cleared, the better the other treatments work.
Whole-abdominal (and pelvic) radiation
Radiation delivered to the entire lining of the abdomen and pelvis after surgery treats the microscopic disease scattered across surfaces that surgery cannot fully reach, lowering the chance of the cancer regrowing there.
Heated intraperitoneal chemotherapy (HIPEC, selected cases)
At some centers, warmed chemotherapy is washed through the abdomen at the time of surgery to treat residual microscopic disease on the abdominal surfaces; its role is still being studied.
Treatment within a clinical trial
Because DSRCT is rare and difficult to cure, enrolling in a clinical trial at an experienced center gives access to the newest combinations and targeted approaches and is strongly encouraged.
Multidisciplinary care at an experienced center
Coordinating chemotherapy, complex surgery, and radiation requires a team that treats this rare cancer regularly, which gives the best chance of delivering the full, intensive plan safely.
How radiation treatment works
Radiation therapy treats desmoplastic small round cell tumor by delivering beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. Its role in DSRCT is shaped by the unusual way this cancer grows: rather than forming a single mass that a surgeon can cut out cleanly, it scatters many nodules across the lining of the abdomen and pelvis, leaving behind countless microscopic tumor cells on these surfaces even after the most aggressive surgery. Because those cells are spread over such a wide area, treating them requires radiation to the whole abdomen and pelvis — known as whole-abdominopelvic radiation — rather than a small, focused field. Given after chemotherapy and surgery have removed the bulk of disease, this whole-cavity treatment aims to sterilize the microscopic cells left across the peritoneal surfaces and lower the chance of the cancer regrowing inside the abdomen, which is where DSRCT most often comes back. Treating such a large volume is demanding, because the kidneys, liver, bowel, and bone marrow all lie within or near the field, so modern intensity-modulated techniques are used to shape the dose as evenly as possible across the target while sparing those organs and limiting side effects. Where bulkier disease remains after surgery, an additional focused boost of radiation can be directed there to improve control. Radiation is also used in a more targeted way for specific deposits outside the abdomen — for example, a spot in the lung or a lymph node — to control a limited area of spread or relieve symptoms. In all of these settings, radiation works hand in hand with chemotherapy and surgery; none alone is sufficient against this aggressive cancer, and the whole-abdominal radiation step is a key part of the standard combination that gives the best chance of controlling the disease.
The main ways radiation is delivered for desmoplastic small round cell tumor (dsrct):
Whole-abdominopelvic radiation (WAP-RT)
Radiation is delivered across the entire abdominal and pelvic cavity to treat the microscopic tumor cells scattered over the peritoneal surfaces after surgery; modern intensity-modulated techniques shape the dose to cover this large area while sparing the kidneys, liver, and bowel as much as possible.
Intensity-modulated radiation (IMRT)
Shaping many beams allows the large abdominal target to be treated more uniformly while reducing dose to the kidneys, liver, and bone marrow, lowering side effects from this demanding treatment.
Focal boost radiation
After whole-abdominal treatment, an extra dose can be directed at areas of bulkier residual disease to improve control where the most tumor remains.
Radiation to distant sites
Focused radiation can control specific deposits outside the abdomen — such as in the lung or a lymph node — to relieve symptoms or treat a limited area of spread.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Multimodal therapy improves outcomes: Studies show that combining intensive chemotherapy, aggressive surgical removal, and whole-abdominal radiation gives better disease control than any single treatment, establishing this trimodality approach as the standard for DSRCT.[1]
Multimodality treatment series in DSRCT
Modern radiation lowers side effects of whole-abdominal treatment: Intensity-modulated radiation allows the entire abdominal cavity to be treated more uniformly while sparing the kidneys, liver, and bone marrow, making this demanding part of treatment safer to deliver.[2]
IMRT whole-abdominopelvic radiotherapy studies in DSRCT
Targeted approaches and trials for a hard-to-cure cancer: Because DSRCT remains difficult to cure, research is testing targeted drugs and novel combinations aimed at the EWSR1-WT1 fusion and related pathways, underscoring the importance of treating this rare cancer within clinical trials.[3]
Targeted-therapy and clinical-trial reports in DSRCT
Common questions
Why does treatment for DSRCT use radiation to the whole abdomen instead of just the tumor? Because of how this cancer grows. DSRCT doesn't form one neat mass — it scatters many tumor nodules across the lining of the abdomen and pelvis, and even the most thorough surgery leaves behind microscopic cells spread over those wide surfaces. A small, focused radiation field would miss most of them. Whole-abdominopelvic radiation treats the entire cavity to sterilize that scattered microscopic disease and lower the chance of the cancer regrowing inside the abdomen, which is where it most often returns. It is demanding to deliver because the kidneys, liver, and bowel sit within the field, so modern techniques are used to shape the dose and protect those organs as much as possible.
Why are so many different treatments needed? Because DSRCT is aggressive and widespread in the abdomen by the time it is usually found, and no single treatment can control it alone. Chemotherapy treats tumor cells throughout the body and shrinks the disease; surgery removes as much of the visible tumor as safely possible; and whole-abdominal radiation treats the microscopic cells left on surfaces surgery can't fully reach. Each step does something the others cannot, and they work best together. This is why care is coordinated by a team experienced with the disease, and why enrolling in a clinical trial — which may add newer targeted approaches to this backbone — is strongly encouraged.
Who tends to get DSRCT? DSRCT mainly affects adolescents and young adults, and it occurs much more often in males than in females. It is rare, and it is driven by a specific gene fusion (EWSR1-WT1) that is not inherited and not caused by anything a person did — it arises by chance in the tumor cells. Confirming that gene fusion on a biopsy is important because DSRCT can look like other 'small round cell' cancers under the microscope, and getting the diagnosis exactly right ensures the intensive, combined treatment this cancer requires is used from the start.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.